TheraRadar
Data updated: May 26, 2026

WELLBUTRIN XL (bupropion hydrochloride)

CNS Approved 2003-08-28

WELLBUTRIN XL is indicated for the treatment of Major Depressive Disorder; Seasonal Affective Disorder.

Source: FDA Label • BAUSCH

How WELLBUTRIN XL Works

While the exact mechanism of action is unknown, the therapeutic effects of bupropion are presumed to be mediated by noradrenergic and dopaminergic mechanisms. The drug functions as a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine. Notably, it does not inhibit the reuptake of serotonin or the activity of monoamine oxidase.

2
Indications
--
Phase 3 Trials
1
Priority Reviews
22
Years on Market

Details

Status
Prescription
First Approved
2003-08-28
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

Companies

Active Ingredient: BUPROPION HYDROCHLORIDE

WELLBUTRIN XL Approval History

2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
56 FDA actions from 2003 to 2025 · 1 indication expansions
Nov 2025 SUPPL
Label · Labeling
May 2024 SUPPL
Label · Labeling
Mar 2022 SUPPL
Label · Labeling

What WELLBUTRIN XL Treats

2 indications

WELLBUTRIN XL is approved for 2 conditions since its original approval in 2003. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
  • Seasonal Affective Disorder
Source: FDA Label

WELLBUTRIN XL Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [ see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of ...

WELLBUTRIN XL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 13 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to WELLBUTRIN XL

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
2 shared
BAUSCH
Shared indications:
Major Depressive DisorderSeasonal Affective Disorder
CONTRAVE
BUPROPION HYDROCHLORIDE
2 shared
NALPROPION
Shared indications:
Major Depressive DisorderSeasonal Affective Disorder
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT04526210 results posted ALXN1840-HV-103 Ph 1 completed Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT03326128 1703346 Ph 2 terminated High Dose Bupropion for Smoking Cessation - Pilot Study
NCT01574703 CATS results posted A3051148 2011-005513-37, CATS Ph 4 completed Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
NCT01456936 EAGLES results posted A3051123 2010-022914-15, EAGLES Ph 4 completed Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
NCT01635972 9766-CL-0044 Ph 1 completed Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

WELLBUTRIN XL FDA Label Details

Indications & Usage

FDA Label (PDF)

WELLBUTRIN XL is indicated for the treatment of Major Depressive Disorder; Seasonal Affective Disorder.

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with...

Track WELLBUTRIN XL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.